Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-06

Study Completion Date

2021-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this project is to determine if hyperinsulinemia attenuates sympathetic nervous system-mediated vasoconstriction in the human leg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation

NCT00001624

Hyperinsulinemia

COMPLETED PHASE1

Role of Angiotensin II in Insulin-induced Microvascular Activity

NCT01024543

Insulin Sensitivity Microcirculation

COMPLETED NA

Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow

NCT00018304

Hypertension

COMPLETED

Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity

NCT03318094

Insulin Resistance Healthy Obesity

ACTIVE_NOT_RECRUITING PHASE1

Microvascular Dilatation After Endogenous Induced Hyperinsulinemia

NCT00742456

Hypertension Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vasoconstriction Healthy Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Insulin

Participants will complete a 60 minute hyperinsulinemic-euglycemic infusion.

Group Type EXPERIMENTAL

Insulin

Intervention Type DRUG

Priming dose then a constant infusion at 40 mU•m-2•min-1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin

Priming dose then a constant infusion at 40 mU•m-2•min-1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy adult men and women;
* 18-45 years of age;
* BMI 18-30 kg/m2;
* non-pregnant/non-breastfeeding;
* non-nicotine users;

Exclusion Criteria

* taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic functions

Self-reported history of:

* hepatic, renal, pulmonary, cardiovascular, or neurological disease;
* stroke or neurovascular disease;
* bleeding/clotting disorders;
* sleep apnea or other sleep disorders;
* diabetes;
* smoking;
* history of alcoholism or substance abuse, excessive alcohol consumption;
* hypertension;
* active cancer;
* autoimmune disease;
* immunosuppressant therapy

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes